BRAIN Biotech AG (XTER:BNN) Accounts Payable & Accrued Expense : €4.81 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Accounts Payable & Accrued Expense?

BRAIN Biotech AG's quarterly accounts payable & accrued expense declined from Sep. 2023 (€6.26 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€4.81 Mil).

BRAIN Biotech AG's annual accounts payable & accrued expense increased from Sep. 2021 (€4.37 Mil) to Sep. 2022 (€7.47 Mil) but then declined from Sep. 2022 (€7.47 Mil) to Sep. 2023 (€6.26 Mil).

BRAIN Biotech AG Accounts Payable & Accrued Expense Historical Data

The historical data trend for BRAIN Biotech AG's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Accounts Payable & Accrued Expense Chart

BRAIN Biotech AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.55

3.93

4.37

7.47

6.26

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															4.36	-	6.26	-	4.81

BRAIN Biotech AG Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

BRAIN Biotech AG (XTER:BNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

BNN:Germany BNN:Germany BNN:Germany

Address

Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website

https://www.brain-biotech.com

BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.

Executives

Dr. Michael Majerus	Supervisory Board
Dr. Georg Kellinghusen	Supervisory Board
Michael Schneiders	Board of Directors
Adriaan Moelker	Board of Directors
Lukas Linnig	Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines